These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 21940156)

  • 1. The influence of immunosuppressive agents on BK virus risk following kidney transplantation, and implications for choice of regimen.
    Suwelack B; Malyar V; Koch M; Sester M; Sommerer C
    Transplant Rev (Orlando); 2012 Jul; 26(3):201-11. PubMed ID: 21940156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BK virus replication following kidney transplant: does the choice of immunosuppressive regimen influence outcomes?
    Acott P; Babel N
    Ann Transplant; 2012; 17(1):86-99. PubMed ID: 22466913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conversion from tacrolimus-mycophenolate mofetil to tacrolimus-mTOR immunosuppression after kidney-pancreas transplantation reduces the incidence of both BK and CMV viremia.
    Knight RJ; Graviss EA; Nguyen DT; Kuten SA; Patel SJ; Gaber L; Gaber AO
    Clin Transplant; 2018 Jun; 32(6):e13265. PubMed ID: 29676018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CMV and BKPyV Infections in Renal Transplant Recipients Receiving an mTOR Inhibitor-Based Regimen Versus a CNI-Based Regimen: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials.
    Mallat SG; Tanios BY; Itani HS; Lotfi T; McMullan C; Gabardi S; Akl EA; Azzi JR
    Clin J Am Soc Nephrol; 2017 Aug; 12(8):1321-1336. PubMed ID: 28576905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of BK polyomavirus infection after kidney transplantation is independent of type of immunosuppressive therapy.
    Radtke J; Dietze N; Fischer L; Achilles EG; Li J; Scheidat S; Thaiss F; Nashan B; Koch M
    Transpl Infect Dis; 2016 Dec; 18(6):850-855. PubMed ID: 27639176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conversion to a sirolimus-based regimen is associated with lower incidence of BK viremia in low-risk kidney transplant recipients.
    Tohme FA; Kalil RS; Thomas CP
    Transpl Infect Dis; 2015 Feb; 17(1):66-72. PubMed ID: 25582442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive Factors of BK Virus Development in Kidney Transplant Recipients and the Effect of Low-Dose Tacrolimus Plus Everolimus on Clinical Outcomes.
    Yilmaz VT; Kisaoglu A; Avanaz A; Dandin O; Ozel D; Mutlu D; Akkaya B; Aydinli B; Kocak H
    Exp Clin Transplant; 2023 Sep; 21(9):727-734. PubMed ID: 37885288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The status of BK polyomavirus replication in adult renal transplant recipients in northeastern Poland.
    Naumnik B; Kowalewska J; Zalewski G; Charkiewicz R; Myśliwiec M
    Transplant Proc; 2011 Oct; 43(8):2976-84. PubMed ID: 21996205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BK viremia surveillance after kidney transplant: single-center experience during a change from cyclosporine-to lower-dose tacrolimus-based primary immunosuppression regimen.
    Geddes CC; Gunson R; Mazonakis E; Wan R; Thomson L; Clancy M; Carman WF
    Transpl Infect Dis; 2011 Apr; 13(2):109-16. PubMed ID: 21457419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of immune suppressive agents on the BK-Polyomavirus non coding control region.
    Korth J; Anastasiou OE; Verheyen J; Dickow J; Sertznig H; Frericks N; Bleekmann B; Kribben A; Brinkhoff A; Wilde B; Sutter K; Dittmer U; Ciesek S; Witzke O; Widera M
    Antiviral Res; 2018 Nov; 159():68-76. PubMed ID: 30268912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Active management versus minimization of immunosuppressives of BK virus-associated nephropathy after a kidney transplant.
    Halim MA; Al-Otaibi T; Gheith O; Zkaria Z; Mosaad A; Said T; Nair P; Nampoory N
    Exp Clin Transplant; 2014 Dec; 12(6):528-33. PubMed ID: 25489803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Follow-Up of Active Treatment Versus Minimization of Immunosuppressive Agents in Patients With BK Virus-Associated Nephropathy After Kidney Transplant.
    Halim MA; Al-Otaibi T; Gheith O; Mosaad A; Zakaria Z; Said T; Nair P; Nampoory NM
    Exp Clin Transplant; 2016 Feb; 14(1):58-65. PubMed ID: 26862825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BK Polyomavirus Replication in Renal Tubular Epithelial Cells Is Inhibited by Sirolimus, but Activated by Tacrolimus Through a Pathway Involving FKBP-12.
    Hirsch HH; Yakhontova K; Lu M; Manzetti J
    Am J Transplant; 2016 Mar; 16(3):821-32. PubMed ID: 26639422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of tacrolimus metabolism rate on BKV infection after kidney transplantation.
    Thölking G; Schmidt C; Koch R; Schuette-Nuetgen K; Pabst D; Wolters H; Kabar I; Hüsing A; Pavenstädt H; Reuter S; Suwelack B
    Sci Rep; 2016 Aug; 6():32273. PubMed ID: 27573493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of Leflunomide and Everolimus for treatment of BK virus nephropathy.
    Jaw J; Hill P; Goodman D
    Nephrology (Carlton); 2017 Apr; 22(4):326-329. PubMed ID: 28247521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Everolimus leads to a lower risk of BKV viremia than mycophenolic acid in de novo renal transplantation patients: a single-center experience.
    Moscarelli L; Caroti L; Antognoli G; Zanazzi M; Di Maria L; Carta P; Minetti E
    Clin Transplant; 2013; 27(4):546-54. PubMed ID: 23758330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mycophenolate Mofetil Withdrawal With Conversion to Everolimus to Treat BK Virus Infection in Kidney Transplant Recipients.
    Wojciechowski D; Chandran S; Webber A; Hirose R; Vincenti F
    Transplant Proc; 2017 Oct; 49(8):1773-1778. PubMed ID: 28923623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pilot conversion trial from mycophenolic acid to everolimus in ABO-incompatible kidney-transplant recipients with BK viruria and/or viremia.
    Belliere J; Kamar N; Mengelle C; Allal A; Sallusto F; Doumerc N; Game X; Congy-Jolivet N; Esposito L; Debiol B; Rostaing L
    Transpl Int; 2016 Mar; 29(3):315-22. PubMed ID: 26575959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunosuppression, BK polyomavirus infections, and BK polyomavirus-specific T cells after pediatric kidney transplantation.
    Ahlenstiel-Grunow T; Pape L
    Pediatr Nephrol; 2020 Apr; 35(4):625-631. PubMed ID: 31858227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative analysis of clinical outcomes between conversion to mTOR inhibitor and calcineurin inhibitor reduction in managing BK viremia among kidney transplant patients.
    Cho A; Park S; Han A; Ha J; Park JB; Lee KW; Min S
    Sci Rep; 2024 Jun; 14(1):12855. PubMed ID: 38834615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.